Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results
|
Neoleukin Therapeutics, Inc. (AQXP)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/10/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Exercised (in-or-at-the-money) 57,049 options to buy
@ $0 Exercised (in-or-at-the-money) 535,601 options to buy
@ $0 |
|
08/17/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Bought 143,519 shares
@ $0.6308, valued at
$90.5k
Bought 1,740,581 shares
@ $0.6308, valued at
$1.1M
Bought 358 shares
@ $0.665, valued at
$238.1 Bought 4,342 shares
@ $0.665, valued at
$2.9k
Bought 17,124 shares
@ $0.6805, valued at
$11.7k
Bought 207,676 shares
@ $0.6805, valued at
$141.3k
Bought 366 shares
@ $0.6828, valued at
$249.9 Bought 4,434 shares
@ $0.6828, valued at
$3k
Bought 7,676 shares
@ $0.6924, valued at
$5.3k
Bought 93,091 shares
@ $0.6924, valued at
$64.5k
Bought 5,041 shares
@ $0.6928, valued at
$3.5k
|
|
08/14/2023 |
4
| Smith Sean Michael (Interim CFO, Prin Acct Off) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Sold 1,323 shares
@ $0.6184, valued at
$818.1 Exercised 5,000 restricted stock units
@ $0 |
|
06/12/2023 |
4
| BAKER BROS. ADVISORS LP (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $0.79, valued at
$19.8k
|
|
06/09/2023 |
4
| SIMPSON TODD E (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $0.79, valued at
$19.8k
|
|
06/09/2023 |
4
| PALEKAR ROHAN (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $0.79, valued at
$19.8k
|
|
06/09/2023 |
4
| Noonberg Sarah B. (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $0.79, valued at
$19.8k
|
|
06/09/2023 |
4
| Lavelle Erin (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $0.79, valued at
$19.8k
|
|
06/09/2023 |
4
| Babler Martin (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $0.79, valued at
$19.8k
|
|
04/04/2023 |
4
| Patel Priti (Former Chief Medical Officer) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Sold 3,769 shares
@ $0.6919, valued at
$2.6k
Exercised 10,000 restricted stock units
@ $0 |
|
02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/12/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/04/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/04/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/04/2022 |
4
| Patel Priti (Chief Medical Officer) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 250,000 options to buy
@ $0.99, valued at
$247.5k
|
|
08/04/2022 |
4
| DRACHMAN JONATHAN G (President and CEO) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 350,000 options to buy
@ $0.99, valued at
$346.5k
|
|
08/04/2022 |
4
| Cochener Donna (General Counsel, SVP Legal) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 100,000 options to buy
@ $0.99, valued at
$99k
|
|
05/16/2022 |
4
| SIMPSON TODD E (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $1.07, valued at
$26.8k
|
|
05/16/2022 |
4
| PALEKAR ROHAN (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $1.07, valued at
$26.8k
|
|
05/16/2022 |
4
| Noonberg Sarah B. (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $1.07, valued at
$26.8k
|
|
05/16/2022 |
4
| Lavelle Erin (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $1.07, valued at
$26.8k
|
|
05/16/2022 |
4
| Babler Martin (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $1.07, valued at
$26.8k
|
|
05/16/2022 |
4
| BAKER BROS. ADVISORS LP (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $1.07, valued at
$26.8k
|
|
05/03/2022 |
4
| Patel Priti (Chief Medical Officer) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Sold 5,538 shares
@ $1.2186, valued at
$6.7k
Exercised 10,000 restricted stock units
@ $0 |
|
03/15/2022 |
4
| Cochener Donna (General Counsel, SVP Legal) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 400,000 options to buy
@ $1.81, valued at
$724k
|
|
03/04/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/03/2022 |
4
| Smith Sean Michael (Principal Accounting Officer) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 80,000 options to buy
@ $2.72, valued at
$217.6k
|
|
02/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/26/2021 |
4
| DRACHMAN JONATHAN G (President and CEO) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Bought 100,000 shares
@ $6.111, valued at
$611.1k
Bought 25,000 shares
@ $6.449, valued at
$161.2k
Bought 25,000 shares
@ $6.449, valued at
$161.2k
|
|
08/05/2021 |
4
| Walkey Carl (Senior Vice President) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 100,000 options to buy
@ $6.8, valued at
$680k
|
|
08/05/2021 |
4
| Vance Holly (General Counsel) has filed a Form 4 on Neoleukin Therapeutics, Inc.
Txns:
| Granted 100,000 options to buy
@ $6.8, valued at
$680k
|
|
|
|
|